Idea Rankings

Migration, Crosslink

📖

Idea Rankings

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-rankings

📖 Wiki Page

idea948 wordssynced 2026-04-02

Introduction

This page ranks therapeutic concepts and ideas for neurodegenerative diseases based on mechanistic strength, development feasibility, and clinical potential. [@cummings2024]

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

| Rank | Idea | Target | Evidence | Feasibility | [@kalia2023]
|------|------|--------|----------|-------------|
| 1 | Triple amyloid-[tau](/proteins/tau)-inflammation | Multiple | High | Moderate |
| 2 | APOE4-specific immunotherapy | Amyloid | High | High |
| 3 | Tau vaccination with adjuvant | Tau | Moderate | High |
| 4 | Synaptic regeneration | Neural repair | Low | Low |
| 5 | Metabolic enhancement | Mitochondria | Moderate | Moderate |

Symptomatic (by efficacy)

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | GLP-1/GIP dual agonism | Metabolism | High | High |
| 2 | AMPA modulators | Glutamate | Moderate | High |
| 3 | PDE inhibitors | cAMP | Moderate | Moderate |
| 4 | 5-HT6 antagonists | Serotonin | Moderate | Moderate |

Top Parkinson's Disease Ideas

Disease-Modifying

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | Alpha-synuclein aggregation inhibitor | α-syn | Moderate | High |
| 2 | GBA gene therapy augmentation | Glucocerebrosidase | Moderate | Moderate |
| 3 | LRRK2 kinase inhibitor | LRRK2 | High | High |
| 4 | Microglial modulation | Neuroinflammation | Moderate | Moderate |

Symptomatic

...

Introduction

This page ranks therapeutic concepts and ideas for neurodegenerative diseases based on mechanistic strength, development feasibility, and clinical potential. [@cummings2024]

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

| Rank | Idea | Target | Evidence | Feasibility | [@kalia2023]
|------|------|--------|----------|-------------|
| 1 | Triple amyloid-[tau](/proteins/tau)-inflammation | Multiple | High | Moderate |
| 2 | APOE4-specific immunotherapy | Amyloid | High | High |
| 3 | Tau vaccination with adjuvant | Tau | Moderate | High |
| 4 | Synaptic regeneration | Neural repair | Low | Low |
| 5 | Metabolic enhancement | Mitochondria | Moderate | Moderate |

Symptomatic (by efficacy)

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | GLP-1/GIP dual agonism | Metabolism | High | High |
| 2 | AMPA modulators | Glutamate | Moderate | High |
| 3 | PDE inhibitors | cAMP | Moderate | Moderate |
| 4 | 5-HT6 antagonists | Serotonin | Moderate | Moderate |

Top Parkinson's Disease Ideas

Disease-Modifying

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | Alpha-synuclein aggregation inhibitor | α-syn | Moderate | High |
| 2 | GBA gene therapy augmentation | Glucocerebrosidase | Moderate | Moderate |
| 3 | LRRK2 kinase inhibitor | LRRK2 | High | High |
| 4 | Microglial modulation | Neuroinflammation | Moderate | Moderate |

Symptomatic

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | Long-acting dopamine agonist | Dopamine | High | High |
| 2 | Adenosine A2A antagonist | adenosine | Moderate | High |
| 3 | Levodopa-sparing combinations | Multiple | Moderate | Moderate |

Top ALS Ideas

| Rank | Idea | Target | Evidence | Feasibility |
|------|------|--------|----------|-------------|
| 1 | SOD1 gene silencing | SOD1 | High | High |
| 2 | [C9orf72](/entities/c9orf72)-targeted ASO | C9orf72 | High | High |
| 3 | Antisense for FUS | FUS | Moderate | High |
| 4 | Muscle strengtheners | Muscle | Moderate | Moderate |
| 5 | Metabolic modulators | Energy | Low | Moderate |

Innovation Rankings

Novel Mechanisms

| Rank | Idea | Innovation | Risk |
|------|------|------------|------|
| 1 | Epigenetic modulation | Very High | High |
| 2 | [Microbiome](/entities/microbiome)-based therapy | High | Moderate |
| 3 | Exosome therapeutics | High | Moderate |
| 4 | Optogenetic approaches | Very High | Very High |
| 5 | Gene editing (CRISPR) | Very High | High |

Repurposing Potential

| Rank | Drug | Original Use | Repurpose Score |
|------|------|--------------|-----------------|
| 1 | Metformin | Diabetes | 85 |
| 2 | Ibuprofen | Pain/ inflammation | 80 |
| 3 | Saracatinib | Cancer | 75 |
| 4 | Losartan | Hypertension | 70 |
| 5 | Valproic acid | Epilepsy | 65 |

Development Readiness

Near-Term Opportunities

GLP-1 agonists for AD: Existing diabetic drugs, strong evidence

Tau immunotherapy: Multiple programs in clinic

LRRK2 inhibitors: Genetic validation, first programs in clinic

Mid-Term Opportunities

Alpha-synuclein aggregation inhibitors: Phase 2 data coming

Gene therapies: Several IND-enabling

Combination approaches: Rationale established

Long-Term Opportunities

Regenerative medicine: Stem cells, tissue engineering

Gene editing: CRISPR applications

Precision medicine: Mutation-specific approaches

Patient Impact Potential

| Idea | Impact | Timeline | Unmet Need |
|------|--------|----------|------------|
| Disease modification | Very High | 5-10 years | High |
| Early detection + treatment | Very High | 3-5 years | Very High |
| Symptom control | Moderate | 1-3 years | High |
| Prevention | Very High | 10+ years | Very High |

[Ideas Index](/ideas)
[Ideas Overview](/ideas/overview)
[Treatments](/therapeutics)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-Links

Disease Pathways

[Alzheimer's Disease](/diseases/alzheimers-disease) — Primary target disease
[Parkinson's Disease](/diseases/parkinsons-disease) — Primary target disease
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Primary target disease

Key Therapeutic Targets

[Amyloid Beta](/proteins/amyloid-beta) — AD therapeutic target
[Tau Protein](/proteins/tau) — AD/PD therapeutic target
[Alpha-Synuclein](/proteins/alpha-synuclein) — PD therapeutic target
[LRRK2](/genes/lrrk2) — PD genetic target
[GBA](/genes/gba) — PD genetic target
[SOD1](/genes/sod1) — ALS genetic target
[C9orf72](/genes/c9orf72) — ALS/FTD genetic target

Mechanism Pathways

[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis) — AD mechanism
[Synaptic Plasticity](/mechanisms/synaptic-plasticity) — AD/PD mechanism
[Neuroinflammation](/mechanisms/neuroinflammation) — AD/PD/ALS mechanism
[Mitophagy Pathway](/mechanisms/mitophagy) — PD mechanism

[Novel Therapy Index](/ideas/novel-therapy-index) — Comprehensive therapy rankings
[GLP-1 Agonists for Neurodegeneration](/ideas/combo-sirt1-nad-epigenetic-metabolic) — Metabolic therapy

Coverage Gaps

The following areas need additional content or pages:

Uncovered Therapeutic Areas

PSP (Progressive Supranuclear Palsy): No dedicated therapeutic ideas section
CBS (Corticobasal Syndrome): No dedicated therapeutic ideas section
MSA (Multiple System Atrophy): No dedicated therapeutic ideas section
FTD (Frontotemporal Dementia): Limited therapeutic ideas coverage
DLB (Dementia with Lewy Bodies): No dedicated therapeutic ideas section

Underdeveloped Categories

Combination therapies: Limited coverage of multi-target approaches
Preventive strategies: Minimal content on prevention approaches
Biomarker-driven therapies: Lacking integration with diagnostic content
Gene therapy modalities: AAV, ASO, and CRISPR approaches need expansion

Missing Cross-Links

Links to mechanism pages for each therapeutic approach
Links to relevant clinical trial pages
Links to target protein/gene pages

References

[Cummings J, et al., Drug development. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13802)

[Kalia LV, et al., Parkinson's disease. Lancet Neurol. 2023 (2023)](https://doi.org/10.1016/S1474-4422(23)

📖 View canonical wiki page →

Related Entities

ideas-rankings

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-rankings
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-42af9fa3afcf
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-rankings'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

90%

Debates

0

Incoming

18

Outgoing

24

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Idea Rankings

Introduction

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

Symptomatic (by efficacy)

Top Parkinson's Disease Ideas

Disease-Modifying

Symptomatic

Introduction

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

Symptomatic (by efficacy)

Top Parkinson's Disease Ideas

Disease-Modifying

Symptomatic

Top ALS Ideas

Innovation Rankings

Novel Mechanisms

Repurposing Potential

Development Readiness

Near-Term Opportunities

Mid-Term Opportunities

Long-Term Opportunities

Patient Impact Potential

See Also

External Links

Cross-Links

Disease Pathways

Key Therapeutic Targets

Mechanism Pathways

Coverage Gaps

Uncovered Therapeutic Areas

Underdeveloped Categories

Missing Cross-Links

References

💬 Discussion

📗 Cite This Artifact

Idea Rankings

Introduction

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

Symptomatic (by efficacy)

Top Parkinson's Disease Ideas

Disease-Modifying

Symptomatic

Introduction

Top Alzheimer's Disease Ideas

Disease-Modifying (by mechanistic strength)

Symptomatic (by efficacy)

Top Parkinson's Disease Ideas

Disease-Modifying

Symptomatic

Top ALS Ideas

Innovation Rankings

Novel Mechanisms

Repurposing Potential

Development Readiness

Near-Term Opportunities

Mid-Term Opportunities

Long-Term Opportunities

Patient Impact Potential

Related Pages

See Also

External Links

Cross-Links

Disease Pathways

Key Therapeutic Targets

Mechanism Pathways

Related Therapy Ideas

Coverage Gaps

Uncovered Therapeutic Areas

Underdeveloped Categories

Missing Cross-Links

Related Pages

References

💬 Discussion